Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_06c87200cf96acdabeae38cd1101927d |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5383 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5383 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
filingDate |
2015-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2018-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60d3f81b2f5c123e018b96b33820591e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e62d6cacf655768db1b33ec682ac2057 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0db26d0acf79c1240a7ab0c8eedc595b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bb686fa003daa2fa72815fb1d673981 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68e4a750187d3291d5b24136258d7f49 |
publicationDate |
2018-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-9968616-B2 |
titleOfInvention |
Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening |
abstract |
Using molecular docking screening, a few therapeutical compounds including trovafloxacin and levofloxacin have been first identified as potential inhibitors of fatty acid binding protein 4 (FABP4). The present invention provides a novel use of levofloxacin as an inhibitor of FABP4 and a drug for the treatment of metabolic diseases or a cardiovascular diseases. The present invention further provides a method of using levofloxacin to inhibit FABP4, or to inhibit adipolysis in adipocytes. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112057454-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022056736-A1 |
priorityDate |
2014-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |